Regeneron Ventures leads $75 million Series A for eczema-focused antibody startup Infinimmune
Infinimmune, a Bay Area biotech developing antibody therapies for eczema, announced a $75 million Series A financing round.
The round was co-led by Regeneron Ventures and Playground Global, with participation from RA Capital Management, Forge Life Science Partners, Goldcrest Capital and existing backer Merck & Co.
Regeneron's involvement signals interest in a potential competitor to its own eczema drug Dupixet, as Infinimmune's lead candidate IFX-201 targets interleukin-13, a mechanism also used by Dupixet.
Company co-founder and CEO Wyatt McDonnell said the funding will help advance the antibody platform and develop complementary molecules for the complex, multifactorial disease.
This writeup was produced by pharmadog from original reporting by Fierce Biotech.
Original headline: “Regeneron backs $75M series A for antibody upstart Infinimmune”
read at Fierce Biotech ↗
comments(0)
5-min edit window · permanent after that